Elpiscience’s $100M series B provides path to IPO

Elpiscience hopes a $100 million series B round led by Hyfinity Investments will enable the company to expand its immuno-oncology pipeline and provide enough runway to carry it to an IPO, Ming Fang, head of global BD, told BioCentury.

New investors Tencent, GTJA Investment Group, Dyee Capital, Oriza Holdings, Ming Bioventures, WisdoMont and Parkway Global invested in the round, as did existing investors Lilly Asia Ventures (LAV), Hillhouse Capital Group and CDH Investments. ...